| Name | Title | Contact Details |
|---|---|---|
Gianela G. |
Human Resources | Profile |
Alexander Azoy |
Chief Accounting Officer (CAO) | Profile |
Jeffrey Lammers |
Director, Clinical Supply Chain Operations | Profile |
Ester Fernandez-Salas |
Senior Director R&D Biology | Profile |
manshiu leung |
Executive Director, Small Molecule Drug Product Development & GMP Ma | Profile |
The combined characteristics of a modern machine (with a touch of humanity) and mythical creature symbolizes Lykan Bioscience™ as a company. The team at Lykan Bioscience operates with a highly advanced way of thinking. We offer our clients speed, agility, and control while accelerating their cell and gene therapy products from clinical through to commercial manufacturing. As part of your team, our Manufacturing Services Organization™ (MSO) will transform what is traditionally offered in the CGT industry, as we guide you through your manufacturing journey. Our mission is to partner with our clients, to maximize patient accessibility and expedite time to market for cell-based therapies.
Deka BioSciences, Inc. is committed to developing and delivering life-changing medicines to patients with cancer and inflammatory diseases.
Gen Trak (Main) is a Liberty, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Senda Biosciences, Inc. is uniquely positioned to transform human health by harnessing millions of years of evolution to program targeted, potent and tunable medicines. Nature has provided the codes to program human cells – both within the cell (mRNA), and, remarkably, to the cell - using what surrounds it. The trillions of non-human cells in the human ecosystem have evolved natural nanoparticles that precisely shuttle biomolecules into human cells, providing the missing pieces to fully unlock programmable medicines. Senda`s proprietary platform includes the first-ever atlas of nature-derived programmable systems at the molecular level and across all kingdoms of life – accessing the entire code provided by nature required to program cells. With this platform, Senda is developing a new class of SendRNA™ medicines. The unique properties of these medicines create new frontiers for mRNA therapeutics and vaccines for infectious, genetic, autoimmune, and metabolic diseases and oncology indications – with further potential to transform the gene editing and protein-based therapy landscapes as well. Based in Cambridge, MA, Senda was founded by Flagship Pioneering.
ProteoCell Biotechnologies Inc. is a Laval, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.